Janssen Pharmaceutical Inc.
NEWS
Genmab A/S is seeking a new arbitration ruling against Janssen seeking $405 million-plus interest in accrued milestone payments for Darzalex Faspro.
It was an extraordinarily busy week for clinical trial news and updates due to several prominent international conferences. Here’s a look at some of the highlights.
Aslan partners with Johns Hopkins and Duke, Editas joins forces with Immatics, Yumanity (soon to be Kineta, Inc.) teams with Janssen, Serotiny & Janssen Biotech and Ginkgo and Novo Nordisk.
Primary seven-year data from Janssen’s (Johnson & Johnson) Phase III trial of Imbruvica (ibrutinib) in lymphoma demonstrated positive survival outcomes.
A roundup of last week’s top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
Janssen shared positive updates from ongoing trials on candidate therapies for Crohn’s disease and ulcerative colitis at Digestive Disease Week in San Diego, California.
Janssen’s Tremfya, an IL-23 inhibitor, is showing an ability to separate itself from AbbVie’s Skyrizi in preventing the activation of cells that drive inflammation.
Scientists in New Zealand have found that mRNA-based COVID-19 vaccines produce greater antibody levels compared to adenovirus vector-based ones across major COVID-19 variants.
Janssen discontinued the development partnership due to advancements made by other companies against the human papillomavirus and its own changing strategic priorities.
JOBS
IN THE PRESS